Line probe and automated real-time PCR TB assays warrant adherence to strict quality assurance measures

International Journal of Tuberculosis and Lung Disease

Volumn 16, Issue 5, 2012, Pages 705-706

  Somoskovi, Akos ^a   Parsons, Linda M ^b   Gutierrez, Cristina ^a   Lee, Evan ^c   Salfinger, Max ^d  

^a FOUNDATION FOR INNOVATIVE NEW DIAGNOSTICS   (Switzerland)

^b CLEMSON UNIVERSITY   (United States)

^c Global Health Programs and Access   (Switzerland)

^d FLORIDA DEPARTMENT OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; RIFAMPICIN;

ACID FAST BACTERIUM; ANALYTICAL ERROR; CONTROL; DATA ANALYSIS; DIAGNOSTIC TEST; DNA EXTRACTION; HIGH RISK PATIENT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LETTER; LIMIT OF DETECTION; LINE PROBE ASSAY; MICROBIAL CONTAMINATION; MIXED INFECTION; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; QUALITY CONTROL; REAL TIME POLYMERASE CHAIN REACTION; RELIABILITY;

AUTOMATION; GUIDELINE ADHERENCE; HUMANS; MOLECULAR DIAGNOSTIC TECHNIQUES; POLYMERASE CHAIN REACTION; QUALITY ASSURANCE, HEALTH CARE; TIME FACTORS; TUBERCULOSIS; TUBERCULOSIS, MULTIDRUG-RESISTANT; WORLD HEALTH ORGANIZATION;

EID: 84859731196     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: 10.5588/ijtld.12.0078     Document Type: Letter

References (5)

1. World Health Organization. Policy statement. Molecular line probe assays for rapid screening of patients at risk of multidrug-resistant tuberculosis (MDR-TB). Geneva, Switzerland: WHO, 2008. http://www.who.int/tb/features- archive/policy-statement. pdf Accessed January 2012.
2. World Health Organization. Policy statement. Automated real-time nucleic acid amplification technology for rapid and simultaneous detection of tuberculosis and rifampicin resistance: Xpert MTB/RIF system. Geneva, Switzerland: WHO, 2011. http://whqlibdoc.who.int/publications/2011/ 9789241501545-eng.pdf Accessed January 2012.
3. Van Deun A, Barrera L, Bastian I, et al. Mycobacterium tuberculosis strains with highly discordant rifampin susceptibility test results. J Clin Microbiol 2009; 47: 3501-3506.
4. Mukinda F K, Theron D, van der Spuy G D, et al. Rise in r ifampin-monoresistant tuberculosis in Western Cape, South A frica. Int J Tuberc Lung Dis 2012; 16: 196-202.
5. Van Rie A, Mellet K, John M-A, et al. False-positive rifampicin resistance on Xpert® MTB/RIF: case report and clinical implications. Int J Tuberc Lung Dis 2012; 16: 206-208.